Donanemab

Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N-terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research .


Cat. No.: EX-A7757R	Purity: >98%

	Chemical structure of Donanemab

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock	Quantity	Order
1mg	get quote
5mg	get quote
10mg	get quote

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	1931944-80-7
Purity	>98%
Color	Colorless to light yellow
State	Liquid

Reference:	[1].Stephen Loucian Lowe, et al. Donanemab (LY3002813) dose-escalation study in Alzheimer's disease. Alzheimers Dement (N Y). 2021 Feb 14;7(1):e12112. [2].Mark A Mintun, et al. Donanemab in Early Alzheimer's Disease. N Engl J Med. 2021 May 6;384(18):1691-1704.
CoA	CoA of Donanemab


		Search